Daniel Gallagher, then a nominee for the U.S. Securities and Exchange Commission, speaks before the Senate Banking Committee in Washington, D.C., U.S., on June 14, 2011. Photo: Andrew Harrer/Bloomberg

Daniel Gallagher, a former commissioner with the U.S. Securities and Exchange Commission whose background includes stints in the financial services and pharmaceuticals industries, is returning to Wilmer Cutler Pickering Hale and Dorr as a partner.

For the last two years Gallagher has been chief legal officer at Mylan, a leading generic drug maker. He plans to leave Mylan in April and to begin practicing out of Wilmer’s Washington, D.C., and New York offices after Labor Day, serving as deputy chair of the firm’s securities department.

“We’re thrilled to have Dan back at the firm,” said Robert Novick, Wilmer’s co-managing partner, in a statement announcing the move. “Dan is a superb lawyer who has had a distinguished career in the public and corporate sectors, and returns to the firm with a broad range of skills and experience.”

Gallagher has boomeranged back and forth from Wilmer several times. After law school at The Catholic University of America, he represented clients involved in SEC proceedings as an associate in the firm’s securities department. He left Wilmer in 2004 to join Fiserv Securities Inc. as senior vice president and general counsel, but later returned as counsel.

He became a staffer at the SEC in 2006, serving in the midst of the financial crisis in positions including as deputy director and co-acting director of the division of trading and markets from 2008 to 2010. Gallagher returned to Wilmer again in 2010 before joining the SEC as commissioner from 2011 to 2015.

After leaving the SEC, Gallagher was president at Patomak Global Partners, a financial services consulting firm founded by another former SEC commissioner, Paul Atkins. Gallagher’s first job at the SEC was as counsel to then-commissioner Atkins.

Gallagher was appointed CLO at Mylan in April 2017, in the wake of Mylan facing scrutiny over price increases for the EpiPen, its allergy injection medical device. In October 2016 the company announced it would pay $465 million to resolve claims that it had overcharged the government for the device.

Mylan has not yet publicly announced Gallagher’s successor as CLO.

When Gallagher, 46, returns to Wilmer as deputy chair of its securities department, he’ll be working alongside practice chair William McLucas.

“He’s the perfect addition to our leadership team,” McLucas said in a statement. “We are excited that he will be our partner again.”